Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery

Kumar, Atul; Nainiwal, Sanjeev; Choudhary, Indranil; Tewari, Hem K; Verma, Lalit

doi:10.1046/j.1442-9071.2002.00554.x

Cited by 32 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Although the antifibroblastic action of DNR has been known for over two decades, its safety in various ophthalmic surgeries has been demonstrated in the last decade. DNR has increasingly been used to improve the success rate of ocular surgeries, including strabismus surgery, 7 pterygium surgery, 8 retinal detachment surgery, 9 and in the prevention of PCO following cataract extraction. 10,11 Dadeya et al 16,6 evaluated the safety and efficacy of intraoperative 0.02% DNR in strabismus surgery and pterygium surgery.…”

Section: Daunorubicinmentioning

confidence: 99%

“…They concluded that DNR seemed to be effective to suppress reproliferation, but that care should be taken to avoid postoperative complications. 9,[22][23][24][25] Some workers 10,11 have performed research into use of DNR as an agent for preventing PCO. They noted that DNR could effectively inhibit the proliferation of human lens epithelial cells in vitro at the concentration of 0.5 mg/ml, almost reaching the greatest effect at the concentration of 7.5 mg/ml.…”

Section: Daunorubicinmentioning

confidence: 99%

“…Daunorubicin (DNR) is a glycosidic antimetabolite that inhibits fibroblast proliferation in vitro and in vivo. 6 The antifibroblastic action of DNR has been used both in animal studies and in human subjects to improve the success rate of various ophthalmic surgeries, including strabismus surgery, 7 pterygium surgery, 8 and retinal detachment surgery, 9 and in the prevention of posterior capsular opacification (PCO) following cataract extraction. 10,11 In glaucoma, DNR has been used experimentally and in human subjects to improve the success rate of high-risk GFS by way of a biodegradable slow-release subconjunctival (s/c) implant, as preoperative and postoperative s/c injections following trabeculectomy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of efficacy and safety of daunorubicin in glaucoma filtering surgery

Varma

Sihota

Agarwal

2006

Eye

View full text Add to dashboard Cite

Purpose To evaluate the intraocular pressure (IOP)-lowering effect and ocular side effects of daunorubicin (DNR) in drug-modulated trabeculectomy. Methods A prospective pilot study was conducted in which 21 Asian patients of Indian origin with high risk factors for failure of trabeculectomy were recruited. An approval from research ethics committee and an informed consent from every patient included in the study were obtained. DNR, an antimetabolite with known antifibroblastic action was used intraoperatively. A limbusbased conjunctival flap followed by conventional trabeculectomy was performed in all eyes. During trabeculectomy, a cellulose sponge soaked in 0.2 mg/ml DNR was applied for 3 min at the proposed site of trabeculectomy before preparation of the partial thickness scleral flap. A regular followup was carried out for 1 year where parameters including visual acuity, IOP by applanation tonometry, and slit lamp examination were performed on each visit. An IOP of 21 mmHg or less was taken as criteria for success. Results Following DNR trabeculectomy, the IOP was lowered from baseline preoperative value of 36.1975.9 to 16.0572.52 mmHg at the end of 1 year. Success rate of 81% (17 out of 21 patients) was noted. None of the patients developed corneal epithelial toxicity, hypotony maculopathy, or choroidal detachment. Conclusion The authors feel that intraoperative daunorubicin is safe and effective in lowering IOP in high-risk surgical cases of glaucoma. However, a much larger cohort study over a considerable number of years will eventually demonstrate its safety.

show abstract

Section: Daunorubicinmentioning

confidence: 99%

Section: Daunorubicinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of efficacy and safety of daunorubicin in glaucoma filtering surgery

Varma

Sihota

Agarwal

2006

Eye

View full text Add to dashboard Cite

show abstract

“…Kumar et al [57] recently reported the efficacy of an intravitreal injection of DAU before conclusion of the vitrectomy. However, Esser et al [58] showed that adjuvant intravitreal DAU induces multi-drug resistance (MDR) and proposed that reproliferation in DAU pre-treated patient probably necessitates cotreatment with inhibitors such as verapamil or administration of antiproliferative drug which acts in a MDR-independent fashion.…”

Section: Drug Treatment Of Pvrmentioning

confidence: 97%

Delivery Systems for the Treatment of Proliferative Vitreoretinopathy: Materials, Devices and Colloidal Carriers

Guidetti

Azema²,

Malet-Martino

et al. 2008

CDD

View full text Add to dashboard Cite

Proliferative vitreoretinopathy (PVR), the most serious complication causing retinal detachment surgery to fail, is one of the leading causes of vision-loss in developed countries. The pharmaceutical treatment of this disease, located in the posterior segment of the eye, is problematic because it is difficult to achieve effective drug levels in the vitreous and the retina through conventional forms of administration (topical or systemic). Intravitreal injections can deliver drugs to the retina without the side-effects associated with systemic administration. However, because PVR is a long-term complication and the half-life of most drugs in the vitreous cavity is short, repeated injections are needed but this can cause complications. Recent advances in ocular drug delivery methods and the development of novel bioactive compounds could lead to new ways for the treatment of PVR. This review will summarize recent literature concerning intraocular drug delivery of biopharmaceutical agents for the treatment and prevention of PVR.

show abstract

“…Cependant, cet adjuvant n'a pas amélioré le pronostic fonctionnel et anatomique (réapplication rétinienne en 1 chirurgie dans 65 % vs 54 %, groupe contrôle). Une autre étude [52] a montré un meilleur succès anatomique chez les patients ayant bénéfi-cié du traitement par daunomycine. Cet adjuvant n'est pas actuellement utilisé couramment.…”

Section: Daunomycineunclassified